サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1540840

脈絡膜新生血管市場レポート：製品タイプ、診断、治療タイプ、用途、地域別、2024～2032年

Choroidal Neovascularization Market Report by Product Type, Diagnosis (Fluorescein Angiography, Indocyanine Green Angiography, Spectral Domain Optical Coherence Tomography, and Others), Treatment Type, Application, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 149 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.11円
脈絡膜新生血管市場レポート：製品タイプ、診断、治療タイプ、用途、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の脈絡膜新生血管市場規模は2023年に65億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて6.4%の成長率（CAGR）を示し、2032年までに116億米ドルに達すると予測しています。

脈絡膜新生血管（CNV）とは、ブルッフ膜や網膜色素上皮（RPE）に影響を及ぼす眼の脈絡膜層に新生血管が生じることを指します。その症状には、脂質の滲出、網膜下の血液や液体、中心視野のゆがみ、うねり、黒点などがあります。現在、CNVの診断には、フルオレセイン血管造影（FA）、インドシアニングリーン（ICG）血管造影、光干渉断層計（OCT）スキャンなどの試験が併用されています。その結果に応じて、医師は抗血管内皮増殖因子（VEGF）薬、熱レーザー治療、光線力学的療法（PDT）を処方し、血管の成長を防ぎます。

加齢黄斑変性（ARMD）、眼ヒストプラスマ症、病的近視、血管筋、脈絡膜断裂、脈絡膜と網膜の炎症性疾患の有病率の上昇により、市場は成長を遂げています。さらに、深刻な健康状態に陥りやすい高齢者人口の増加が、市場の成長を後押しするもう1つの重要な要因となっています。さらに、長期持続型抗VEGF薬の採用とともに、併用薬の採用が増加していることも、CNV治療に対する世界の需要を後押ししています。医療インフラの改善や研究開発（R&D）活動への投資の増加など、その他の要因も市場の成長に寄与しています。

本レポートで扱う主要質問

  • 世界の脈絡膜新生血管市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19は世界の脈絡膜新生血管市場にどのような影響を与えたか？
  • 主要地域市場とは？
  • 製品タイプ別の市場内訳は？
  • 診断別の市場内訳は？
  • 治療タイプ別の市場内訳は？
  • 用途別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の脈絡膜新生血管市場の構造と主要参入企業は？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の脈絡膜新生血管市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品タイプ別

  • 静脈内
  • 硝子体内

第7章 市場内訳：診断別

  • フルオレセイン蛍光眼底造影（FA）
  • インドシアニングリーン（ICG）血管造影試験
  • スペクトル領域光干渉断層撮影（OCT）
  • その他

第8章 市場内訳：治療タイプ別

  • 血管新生阻害剤注射
  • 光線力学療法
  • レーザー光凝固術
  • 低線量放射線治療
  • 手術

第9章 市場内訳：用途別

  • 極度の近視
  • 悪性近視変性症
  • 加齢に伴う発達

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Bausch Health Companies Inc.
    • Bayer AG
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche AG
    • MaaT Pharma
    • Novartis AG
    • Pfizer Inc.
    • Quark Pharmaceuticals Inc.（SBI ALApharma Co., Limited）
    • Regeneron Pharmaceuticals Inc.
    • Sanwa Kagaku Kenkyusho Co. Ltd.（SUZUKEN CO., LTD.）
図表

List of Figures

  • Figure 1: Global: Choroidal Neovascularization Market: Major Drivers and Challenges
  • Figure 2: Global: Choroidal Neovascularization Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Choroidal Neovascularization Market: Breakup by Product Type (in %), 2023
  • Figure 4: Global: Choroidal Neovascularization Market: Breakup by Type of Diagnosis (in %), 2023
  • Figure 5: Global: Choroidal Neovascularization Market: Breakup by Treatment Type (in %), 2023
  • Figure 6: Global: Choroidal Neovascularization Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Choroidal Neovascularization Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Choroidal Neovascularization Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Choroidal Neovascularization (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Choroidal Neovascularization (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Choroidal Neovascularization (Intravitreal) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Choroidal Neovascularization (Intravitreal) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Choroidal Neovascularization (Fluorescein Angiography) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Choroidal Neovascularization (Fluorescein Angiography) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Choroidal Neovascularization (Indocyanine Green Angiography) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Choroidal Neovascularization (Indocyanine Green Angiography) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Choroidal Neovascularization (Spectral Domain Optical Coherence Tomography) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Choroidal Neovascularization (Spectral Domain Optical Coherence Tomography) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Choroidal Neovascularization (Other Type of Diagnosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Choroidal Neovascularization (Other Type of Diagnosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Choroidal Neovascularization (Angiogenesis Inhibitors Injection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Choroidal Neovascularization (Angiogenesis Inhibitors Injection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Choroidal Neovascularization (Photodynamic Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Choroidal Neovascularization (Photodynamic Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Choroidal Neovascularization (Laser photocoagulation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Choroidal Neovascularization (Laser photocoagulation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Choroidal Neovascularization (Low-dose Radiation Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Choroidal Neovascularization (Low-dose Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Choroidal Neovascularization (Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Choroidal Neovascularization (Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Choroidal Neovascularization (Extreme Myopia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Choroidal Neovascularization (Extreme Myopia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Choroidal Neovascularization (Malignant Myopic Degeneration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Choroidal Neovascularization (Malignant Myopic Degeneration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Choroidal Neovascularization (Age-Related Developments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Choroidal Neovascularization (Age-Related Developments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: United States: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: United States: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Canada: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Canada: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Asia Pacific: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Asia Pacific: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: China: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: China: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Japan: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Japan: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: India: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: India: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: South Korea: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: South Korea: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Australia: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Australia: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Indonesia: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Indonesia: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Europe: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Europe: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Germany: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Germany: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: France: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: France: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: United Kingdom: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: United Kingdom: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Italy: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Italy: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Spain: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Spain: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Russia: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Russia: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Latin America: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Latin America: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Brazil: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Brazil: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Mexico: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Mexico: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Middle East and Africa: Choroidal Neovascularization Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Middle East and Africa: Choroidal Neovascularization Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Global: Choroidal Neovascularization Industry: SWOT Analysis
  • Figure 86: Global: Choroidal Neovascularization Industry: Value Chain Analysis
  • Figure 87: Global: Choroidal Neovascularization Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Choroidal Neovascularization Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Choroidal Neovascularization Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Choroidal Neovascularization Market Forecast: Breakup by Type of Diagnosis (in Million US$), 2024-2032
  • Table 4: Global: Choroidal Neovascularization Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 5: Global: Choroidal Neovascularization Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 6: Global: Choroidal Neovascularization Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Choroidal Neovascularization Market Structure
  • Table 8: Global: Choroidal Neovascularization Market: Key Players
目次
Product Code: SR112024A2561

The global choroidal neovascularization market size reached US$ 6.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032.

Choroidal neovascularization (CNV) refers to the creation of new blood vessels in the choroid layer of the eyes affecting the Bruch's membrane and retinal pigment epithelium (RPE). Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision. At present, a combination of procedures, such as fluorescein angiography (FA), indocyanine green (ICG) angiography and optical coherence tomography (OCT) scanning, are utilized for diagnosing CNV. As per the results, doctors then prescribe anti-vascular endothelial growth factor (VEGF) drugs, thermal laser treatment and photodynamic therapy (PDT), to prevent the growth of the blood vessels.

The market is experiencing growth on account of the rising prevalence of age-related macular degeneration (ARMD), ocular histoplasmosis, pathologic myopia, angioid streaks, choroidal tears and inflammatory diseases of the choroid and retina. Moreover, the increasing geriatric population, which is more vulnerable to serious health conditions, is acting as another key factor bolstering the market growth. Furthermore, the growing adoption of combination drugs, along with the introduction of long-lasting anti-VEGF drugs, is propelling the demand for CNV treatments worldwide. Other factors, such as improving healthcare infrastructure and the increasing investments in research and development (R&D) activities, are also contributing to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global choroidal neovascularization market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, type of diagnosis, treatment type and application.

Breakup by Product Type:

Intravenous

Intravitreal

Breakup by Type of Diagnosis:

Fluorescein Angiography (FA)

Indocyanine Green (ICG) Angiography

Spectral Domain Optical Coherence Tomography (OCT)

Others

Breakup by Treatment Type:

Angiogenesis Inhibitors Injection

Photodynamic Therapy

Laser photocoagulation

Low-dose Radiation Therapy

Surgery

Breakup by Application:

Extreme Myopia

Malignant Myopic Degeneration

Age-Related Developments

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Bausch Health Companies Inc., Bayer AG, Gilead Sciences, Inc., F. Hoffmann-La Roche AG, MaaT Pharma, Novartis AG, Pfizer Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Regeneron Pharmaceuticals Inc. and Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.).

Key Questions Answered in This Report:

  • How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global choroidal neovascularization market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product type?
  • What is the breakup of the market based on the type of diagnosis?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global choroidal neovascularization market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Choroidal Neovascularization Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Intravenous
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Intravitreal
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Type of Diagnosis

  • 7.1 Fluorescein Angiography (FA)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Indocyanine Green (ICG) Angiography
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Spectral Domain Optical Coherence Tomography (OCT)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Treatment Type

  • 8.1 Angiogenesis Inhibitors Injection
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Photodynamic Therapy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Laser Photocoagulation
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Low-dose Radiation Therapy
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Surgery
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Extreme Myopia
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Malignant Myopic Degeneration
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Age-Related Developments
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Bausch Health Companies Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bayer AG
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Gilead Sciences, Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 MaaT Pharma
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Novartis AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Pfizer Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Quark Pharmaceuticals Inc. (SBI ALApharma Co., Limited)
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Regeneron Pharmaceuticals Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanwa Kagaku Kenkyusho Co. Ltd. (SUZUKEN CO., LTD.)
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio